Q4 Preliminary Figures and 2026 Guidance Make DexCom (DXCM) Look Attractive

Core Insights - DexCom Inc (NASDAQ:DXCM) is recognized as one of the top 12 medical device stocks favored by hedge funds, with a strong bullish sentiment reflected in analyst ratings [1] - The company reported fourth-quarter results with U.S. revenues of $892 million and international revenues of $368 million, achieving year-over-year growth of 11% and 18% respectively, surpassing consensus estimates by nearly 2 percentage points [2] - For FY 2025, management anticipates an adjusted gross margin of approximately 61% and an adjusted operating margin of around 20%-21%, with projected revenues for 2026 between $5.16 billion and $5.25 billion [3] Company Overview - DexCom Inc specializes in continuous glucose monitoring (CGM) systems that assist in managing diabetes and metabolic conditions by providing real-time glucose level tracking [4]